(2-氨基苯基)(4-甲基-1-哌嗪基)甲酮 | 93288-86-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2-氨基苯基)(4-甲基-1-哌嗪基)甲酮
• 中文别名: 1-甲基-4-[2-氨基]苯甲酰哌嗪
• 英文名称: 1-(2-aminobenzoyl)-4-methylpiperazine
• 英文别名: (2-Aminophenyl)(4-methylpiperazin-1-yl)methanone；(2-aminophenyl)-(4-methylpiperazin-1-yl)methanone
• CAS: 93288-86-9
• 化学式: C₁₂H₁₇N₃O
• mdl: MFCD03013018
• 分子量: 219.286
• InChiKey: PEIXOOFVMXCCCT-UHFFFAOYSA-N

物化性质

• 熔点：
  76-79 °C(Solv: benzene (71-43-2))
• 沸点：
  394.0±37.0 °C(Predicted)
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  49.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 (2-氨基苯基)(4-甲基-1-哌嗪基)甲酮 以 水 、 溶剂黄146 为溶剂， 以100%的产率得到1-(2-acetamidobenzoyl)-4-methylpiperazine
  参考文献：
  名称：

  Cervena, Irena; Protiva, Miroslav, Collection of Czechoslovak Chemical Communications, 1984, vol. 49, # 4, p. 1009 - 1020

  摘要：

  DOI：
• 作为产物：
  描述：

  邻氨基三氟甲苯 在 盐酸 作用下， 以 乙醚 、 乙醇 、 xylene 为溶剂， 反应 11.0h， 生成 (2-氨基苯基)(4-甲基-1-哌嗪基)甲酮
  参考文献：
  名称：

  Further studies on the cyclization of aromatic azomethines ortho-substituted with a trifluoromethyl group: synthesis of 2,4-di- or 2,3,4-trisubstituted quinolines

  摘要：

  The scope and limitations of the novel synthetic route to quinolines (Strekowski et al. J. Org. Chem. 1990, 55, 4777) have been studied. A direct condensation of 2-(trifluoromethyl)aniline (1) with methyl aryl ketones, methyl heteroaryl ketones, ethyl aryl ketones, methyl vinyl ketones, 1-indanone, 1-tetralone, camphor, and cyclohexanone provides an easy access to the corresponding ketimines. An indirect one-pot preparation of dialkyl ketimines and C-alkyl-substituted amidines derived from 1, but inaccessible by the direct condensation method, is also presented. All these ketimines and amidines are cyclized in the presence of alkylamide, dialkylamide, or alkoxide bases to give a quinoline containing the base function at C-4. Analysis of byproducts of the base-mediated reactions provides strong support for the originally proposed mechanism of the quinoline formation.

  DOI：

  10.1021/jo00027a037

文献信息

• Urea derivatives as integrin a4 antagonists
  申请人：Jimenez Mayorga Miguel Juan

  公开号：US20070238763A1

  公开（公告）日：2007-10-11

  Novel antagonists of α4β1 integrin and/or α4β7 integrin are described in this application.

  本申请中描述了α4β1整合素和/或α4β7整合素的新型拮抗剂。
• Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors
  申请人：ALLEN David George

  公开号：US20080175914A1

  公开（公告）日：2008-07-24

  The invention relates to a compound of formula (I) or a salt thereof: wherein: R 1 is C 1-4 alkyl, C 1-3 fluoroalkyl, —CH 2 CH 2 OH or —CH 2 CH 2 CO 2 C 1-2 alkyl; R 2 is a hydrogen atom (H), methyl or C 1 fluoroalkyl; R 3 is optionally substituted C 3-8 cycloalkyl or optionally substituted mono-unsaturated-C 5-7 cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n 1 and n 2 independently are 1 or 2; and in which Y is O, S, SO 2 , or NR 10 ; or R 3 is a bicyclic group (dd) or (ee): and wherein X is NR 4 R 5 or OR 5a . The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE 4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

  本发明涉及公式（I）的化合物或其盐： 其中： R1是C1-4烷基，C1-3氟烷基，-CH2CH2OH或-CH2CH2CO2C1-2烷基; R2是氢原子（H），甲基或C1氟烷基; R3是可选取代的C3-8环烷基或可选取代的单不饱和C5-7环烯基或亚公式（aa），（bb）或（cc）的可选取代的杂环基; 其中n1和n2独立地为1或2; Y是O，S，SO2或NR10; 或R3是双环基（dd）或（ee）： 其中X是NR4R5或OR5a。 该化合物是磷酸二酯酶（PDE）抑制剂，特别是PDE4抑制剂。本发明还提供了公式（I）的化合物或其药学上可接受的盐的用途，用于制造治疗和/或预防哺乳动物，如人类的炎症性和/或过敏性疾病的药物，例如慢性阻塞性肺疾病（COPD），哮喘或过敏性鼻炎。
• AMINO PYRIMIDINE ANTICANCER COMPOUNDS
  申请人：APPARI Rama Devi

  公开号：US20110136764A1

  公开（公告）日：2011-06-09

  Compounds of Formula 1, as shown below and defined herein: and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.

  以下为化学式1的化合物，本文中定义：以及其药学上可接受的盐、合成、中间体、制剂和治疗该疾病的方法，包括至少部分由FAK介导的癌症。
• Amino pyrimidine anticancer compounds
  申请人：Appari Rama Devi

  公开号：US08399433B2

  公开（公告）日：2013-03-19

  Compounds of Formula 1, as shown below and defined herein: and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.

  以下式子所示的化合物1及其药学上可接受的盐，合成、中间体、制剂和使用它们治疗疾病的方法，包括至少部分由FAK介导的癌症的治疗方法。
• CERVENA, I.;PROTIVA, M., COLLECT. CZECHOSL. CHEM. COMMUN., 1984, 49, N 4, 1009-1020
  作者：CERVENA, I.、PROTIVA, M.

  DOI：——

  日期：——